JP2013532482A - 遺伝子発現を用いた前立腺癌の予後を定量化する方法 - Google Patents

遺伝子発現を用いた前立腺癌の予後を定量化する方法 Download PDF

Info

Publication number
JP2013532482A
JP2013532482A JP2013521883A JP2013521883A JP2013532482A JP 2013532482 A JP2013532482 A JP 2013532482A JP 2013521883 A JP2013521883 A JP 2013521883A JP 2013521883 A JP2013521883 A JP 2013521883A JP 2013532482 A JP2013532482 A JP 2013532482A
Authority
JP
Japan
Prior art keywords
mir
hsa
gene
expression level
recurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013521883A
Other languages
English (en)
Japanese (ja)
Inventor
シャク，スティーブン
エル． ベイナー，フレデリック
マダラ，タラ
リー，マーク
ペラム，ロバート，ジェイ．
コーエンス，ウエイン
チェルババス，ダイアナ
シー． キファー，マイケル
クレーガー，マイケル
ゴダード，オードリー
ベイカー，ジョフリ，ビー．
Original Assignee
ジェノミック ヘルス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェノミック ヘルス， インコーポレイテッド filed Critical ジェノミック ヘルス， インコーポレイテッド
Publication of JP2013532482A publication Critical patent/JP2013532482A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2013521883A 2010-07-27 2011-07-25 遺伝子発現を用いた前立腺癌の予後を定量化する方法 Pending JP2013532482A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US36821710P 2010-07-27 2010-07-27
US61/368,217 2010-07-27
US41431010P 2010-11-16 2010-11-16
US61/414,310 2010-11-16
US201161485536P 2011-05-12 2011-05-12
US61/485,536 2011-05-12
PCT/US2011/045253 WO2012015765A2 (en) 2010-07-27 2011-07-25 Method for using gene expression to determine prognosis of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016028850A Division JP6246845B2 (ja) 2010-07-27 2016-02-18 遺伝子発現を用いた前立腺癌の予後を定量化する方法

Publications (1)

Publication Number Publication Date
JP2013532482A true JP2013532482A (ja) 2013-08-19

Family

ID=45527113

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013521883A Pending JP2013532482A (ja) 2010-07-27 2011-07-25 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2016028850A Expired - Fee Related JP6246845B2 (ja) 2010-07-27 2016-02-18 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2017219711A Pending JP2018068299A (ja) 2010-07-27 2017-11-15 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2019187371A Expired - Fee Related JP7042784B2 (ja) 2010-07-27 2019-10-11 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2021187716A Pending JP2022031750A (ja) 2010-07-27 2021-11-18 遺伝子発現を用いた前立腺癌の予後を定量化する方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016028850A Expired - Fee Related JP6246845B2 (ja) 2010-07-27 2016-02-18 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2017219711A Pending JP2018068299A (ja) 2010-07-27 2017-11-15 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2019187371A Expired - Fee Related JP7042784B2 (ja) 2010-07-27 2019-10-11 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP2021187716A Pending JP2022031750A (ja) 2010-07-27 2021-11-18 遺伝子発現を用いた前立腺癌の予後を定量化する方法

Country Status (12)

Country Link
US (6) US20120028264A1 (enExample)
EP (5) EP2913405B1 (enExample)
JP (5) JP2013532482A (enExample)
AU (1) AU2011282892B2 (enExample)
CA (2) CA2804626C (enExample)
DK (3) DK2913405T3 (enExample)
ES (4) ES2741745T3 (enExample)
IL (5) IL243205A (enExample)
MX (4) MX346031B (enExample)
NZ (1) NZ607282A (enExample)
SG (3) SG186940A1 (enExample)
WO (1) WO2012015765A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017509351A (ja) * 2013-12-30 2017-04-06 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 前立腺癌遺伝子プロファイル及びその使用方法
JP2018527883A (ja) * 2015-05-29 2018-09-27 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 前立腺がん予後判定の方法
JP2019013255A (ja) * 2012-01-31 2019-01-31 ジェノミック ヘルス， インコーポレイテッド 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
JP2023113680A (ja) * 2019-05-31 2023-08-16 医薬資源研究所株式会社 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2680692A1 (en) * 2007-03-30 2008-10-09 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of prostate cancer
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
EP2591126B1 (en) 2010-07-07 2020-12-30 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
TW201343920A (zh) * 2012-03-29 2013-11-01 財團法人國家衛生研究院 預測前列腺癌預後之分子標記、方法與套組
BR102012007246A2 (pt) * 2012-03-30 2016-02-10 Fundação Antonio Prudente métodos para prognóstico e classificação de resultados de um evento
WO2013155371A1 (en) * 2012-04-12 2013-10-17 Cornell University MiRNA-31 AS A DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC AGENT IN CANCER
GB201207722D0 (en) 2012-05-02 2012-06-13 Bergenbio As Method
US20150218646A1 (en) * 2012-07-20 2015-08-06 Diagnocure Inc Methods, kits and compositions for providing a clinical assessment of prostate cancer
CN102816862A (zh) * 2012-09-19 2012-12-12 南开大学 miRNA 222在前列腺癌血清学诊断试剂盒中的应用
WO2014071226A1 (en) * 2012-11-02 2014-05-08 The Regents Of The University Of California Methods and systems for determining a likelihood of adverse prostate cancer pathology
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
EP3094747B1 (en) * 2014-01-16 2018-11-07 Illumina, Inc. Gene expression panel for prognosis of prostate cancer recurrence
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10801072B2 (en) 2014-09-04 2020-10-13 Miodx Method of analysis allowing avoidance of surgery
WO2016115312A1 (en) 2015-01-14 2016-07-21 Ohio State Innovation Foundation Mirna-based predictive models for diagnosis and prognosis of prostate cancer
JP2018504915A (ja) 2015-02-11 2018-02-22 エクシコン エ／エス 尿中の前立腺癌の早期発見のためのｍｉｃｒｏＲＮＡに基づく方法
CA2977439C (en) 2015-02-27 2025-05-20 Aarhus Universitet MICRORNA-BASED METHOD FOR EVALUATING THE PROGNOSIS OF A PATIENT WITH PROSTATE CANCER
CN104880565A (zh) * 2015-05-04 2015-09-02 贵州省人民医院 Zfp36前列腺癌预后诊断的检测试剂及其试剂盒
US20170107580A1 (en) 2015-10-15 2017-04-20 Dendreon Pharmaceuticals, Inc. Gene expression markers for predicting overall survival in subjects treated with sipuleucel-t
EP3405583B1 (en) * 2016-01-20 2024-04-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for screening and identifying clinically aggressive prostate cancer
EP3411505A4 (en) 2016-02-02 2020-01-15 Guardant Health, Inc. EVIDENCE OF CANCER DEVELOPMENT AND DIAGNOSTICS
WO2017210662A1 (en) * 2016-06-03 2017-12-07 Castle Biosciences, Inc. Methods for predicting risk of recurrence and/or metastasis in soft tissue sarcoma
US10724089B2 (en) 2016-10-06 2020-07-28 The Board Of Trustees Of The University Of Illinois Spatial molecular analysis of tissue
WO2018098241A1 (en) * 2016-11-22 2018-05-31 University Of Rochester Methods of assessing risk of recurrent prostate cancer
GB201619808D0 (en) * 2016-11-23 2017-01-04 Univ London Queen Mary Biomarkers for the prognosis and diagnosis of cancer
CA3089406A1 (en) * 2018-01-25 2019-08-01 Sorbonne Universite Molecular signature and use thereof for the identification of indolent prostate cancer
CA3091647A1 (en) * 2018-02-22 2019-08-29 Liquid Biopsy Research LLC Methods for prostate cancer detection and treatment
WO2020214718A1 (en) * 2019-04-16 2020-10-22 Memorial Sloan Kettering Cancer Center Rrm2 signature genes as prognostic markers in prostate cancer patients
KR20220044504A (ko) * 2019-07-05 2022-04-08 인텔렉슨 게엠베하 개인 hla 패턴의 결정, 예후인자로서의 용도, 표적 유전자 및 치료제
WO2021124455A1 (ja) * 2019-12-17 2021-06-24 株式会社 東芝 分析方法及びキット
EP4077667A1 (en) * 2019-12-19 2022-10-26 F. Hoffmann-La Roche AG Use of sept9 inhibitors for treating hepatitis b virus infection
EP4097479A4 (en) * 2020-01-30 2023-12-20 Arocell AB PREDICTING PATIENT SURVIVAL
EP3885453A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on dna repair genes
US11845993B2 (en) * 2020-03-24 2023-12-19 The Regents Of The University Of Michigan Methods for identifying prostate cancer
WO2022020756A1 (en) * 2020-07-23 2022-01-27 John Mansell Compositions and methods for treating pain and anxiety disorders
ES1277194Y (es) 2021-03-25 2021-11-26 Keyzell Holding Sl Sistema basado en inteligencia artificial para analizar biomarcadores y personalizar tratamientos para cáncer
JPWO2024162265A1 (enExample) 2023-01-30 2024-08-08
CN116640734B (zh) * 2023-06-17 2025-01-24 青岛农业大学 关键基因在体外调控卵母细胞gvbd的用途及干扰片段

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005008213A2 (en) * 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20070212702A1 (en) * 2005-09-12 2007-09-13 Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20090233279A1 (en) * 2005-03-16 2009-09-17 Sidney Kimmel Cancer Center Methods and Compositions for Predicting Death from Cancer and Prostate Cancer Survival Using Gene Expression Signatures
US20090298082A1 (en) * 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
WO2010056993A2 (en) * 2008-11-14 2010-05-20 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000449A1 (en) 1995-06-14 1997-01-03 Aberdeen University Prognostic and therapeutic system for cancer
US6300060B1 (en) 1995-11-09 2001-10-09 Dana-Farber Cancer Institute, Inc. Method for predicting the risk of prostate cancer morbidity and mortality
USRE38490E1 (en) 1995-11-16 2004-04-06 Baylor College Of Medicine Method for identifying metastatic sequences
US5712097A (en) 1996-01-19 1998-01-27 The Johns Hopkins University School Of Medicine Tumor suppressor gene, DPC4
WO1998002748A1 (en) 1996-07-15 1998-01-22 Mayo Foundation For Medical Education And Research Methods to detect hk2 polypeptides
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US6190857B1 (en) 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
AU8403098A (en) 1997-07-15 1999-02-10 Deaconess Hospital Reagents and methods for diagnosis and prognosis of proliferative disor ders
US20020132981A1 (en) 1997-12-03 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
WO1999064627A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
GB2339200B (en) 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
CA2360073C (en) * 1999-01-28 2011-01-18 Gen-Probe Incorporated Probes and primers for detecting prostate specific antigen (psa) in a biological sample
US20030207808A1 (en) 1999-02-18 2003-11-06 Kinneret Savitzky Novel nucleic acid and amino acid sequences
FI990382A0 (fi) * 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
EP1176198A4 (en) 1999-04-09 2002-10-30 Chugai Pharmaceutical Co Ltd FETAL GENES
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
GB9926805D0 (en) 1999-11-13 2000-01-12 Zeneca Ltd Diagnostic methods
DK1246917T3 (da) * 2000-01-13 2009-06-08 Genentech Inc Humane Stra6-polypeptider
US6448086B1 (en) 2000-01-18 2002-09-10 Diagnostic Systems Laboratories, Inc. Insulin-like growth factor system and cancer
US6566130B1 (en) 2000-01-28 2003-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated gene expressed in prostate tissue
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
AU2002216009A1 (en) 2000-11-03 2002-05-15 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
WO2002074156A2 (en) 2001-02-02 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002079411A2 (en) 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
US20040203012A1 (en) 2001-05-25 2004-10-14 Eleftherios Diamandis Method of detecting and monitoring prostate and ovarian cancers
JP2005503779A (ja) 2001-06-10 2005-02-10 アイアールエム，エルエルシー 致死性の高い癌の分子シグネチャー
AU2002337657A1 (en) 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20100297657A1 (en) 2001-08-02 2010-11-25 The Regents Of The University Of Michigan Expression profile of prostate cancer
CA2466502A1 (en) 2001-11-09 2003-05-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
AU2002357747A1 (en) 2001-12-10 2003-06-23 Millennium Pharmaceuticals Inc. Novel genes encoding colon cancer antigens
US6949342B2 (en) 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
US20030215835A1 (en) 2002-01-15 2003-11-20 Zairen Sun Differentially-regulated prostate cancer genes
US20050112705A1 (en) 2002-03-14 2005-05-26 Laurent Bracco Variants of human kallikrein-2 and kallikrein-3 and uses thereof
AUPS187002A0 (en) * 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
WO2004025258A2 (en) 2002-09-10 2004-03-25 Sydney Kimmel Cancer Center Gene segregation and biological sample classification methods
EP1585433A4 (en) 2002-09-25 2008-01-23 Ge Healthcare Sv Corp DETECTION METHODS
WO2004053106A2 (en) 2002-12-05 2004-06-24 Regulome Corporation Profiled regulatory sites useful for gene control
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
WO2004077942A2 (en) 2003-02-28 2004-09-16 Genpath Pharmaceuticals, Incorporated Inducible prostate cancer model
US20070059697A1 (en) 2003-04-15 2007-03-15 Avalon Pharmaceuticals, Inc Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US7659062B2 (en) * 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
JP4680898B2 (ja) 2003-06-24 2011-05-11 ジェノミック ヘルス， インコーポレイテッド 癌再発の可能性の予測
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
EP1656542A4 (en) 2003-07-29 2008-09-03 Bristol Myers Squibb Co BIOMARKER OF MODULATION CYCLIN-DEPENDENT KINASE
AU2004298604B2 (en) 2003-12-15 2010-09-23 The Regents Of The University Of California Molecular signature of the PTEN tumor suppressor
JP2008504803A (ja) 2004-01-09 2008-02-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子発現の細胞型特異的パターン
GB0400976D0 (en) 2004-01-16 2004-02-18 Univ Cambridge Tech Methods of diagnosis
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
WO2005083128A2 (en) 2004-02-25 2005-09-09 University Of South Florida Methods for predicting cancer outcome and gene signatures for use therein
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US8227380B2 (en) 2004-04-29 2012-07-24 Marc Ramael Method and kit for detecting components in a sample
WO2005113816A2 (en) 2004-05-07 2005-12-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
JP2008500057A (ja) 2004-05-27 2008-01-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｉｍｐｄｈ経路の阻害をモニタリングするためのバイオマーカー
JP2008502326A (ja) 2004-06-03 2008-01-31 バイエル・ヘルスケア・アクチェンゲゼルシャフト 癌治療に対する反応を予測およびモニターする方法
WO2006005043A2 (en) 2004-06-30 2006-01-12 Cemines, Inc. Compositions and methods for detecting protein interactions with target dna sequences
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
KR20070052788A (ko) 2004-08-13 2007-05-22 밀레니엄 파머슈티컬스 인코퍼레이티드 전립선암의 확인, 평가, 예방 및 요법을 위한 유전자,조성물, 키트 및 방법
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
CA3061785A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
AU2005308594A1 (en) 2004-11-24 2006-06-01 St George's Enterprises Limited Diagnosis of prostate cancer
WO2006066240A2 (en) 2004-12-17 2006-06-22 Veridex Llc Methods for assessing patients with acute myeloid leukemia
US7943306B2 (en) 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
WO2006089087A2 (en) 2005-02-17 2006-08-24 Dana-Farber Cancer Institute, Inc. Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
US7666595B2 (en) * 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
CA2604689A1 (en) 2005-04-15 2006-10-26 Oncomethylome Sciences, Inc. Methylation markers for diagnosis and treatment of cancers
US20090186024A1 (en) 2005-05-13 2009-07-23 Nevins Joseph R Gene Expression Signatures for Oncogenic Pathway Deregulation
US20080275652A1 (en) 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
WO2006135596A2 (en) 2005-06-06 2006-12-21 The Regents Of The University Of Michigan Prognostic meta signatures and uses thereof
CA2611728A1 (en) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070105133A1 (en) 2005-06-13 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2006339538A1 (en) 2005-11-08 2007-09-13 Euclid Diagnostics Llc Materials and methods for assaying for methylation of CpG islands associated with genes in the evaluation of cancer
CA2631236C (en) 2005-12-01 2019-10-29 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
CA2630597A1 (en) 2005-12-08 2007-06-14 Novartis Ag Effects of inhibitors of fgfr3 on gene transcription
WO2007070621A2 (en) 2005-12-13 2007-06-21 Children's Medical Center Corporation Prognosis indicators for solid human tumors
WO2007075672A2 (en) 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
DK1974058T3 (da) 2006-01-11 2014-09-01 Genomic Health Inc Genekspressionsmarkører til prognosticering af kolorektal cancer
ES2300176B1 (es) * 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
US20070218512A1 (en) 2006-02-28 2007-09-20 Alex Strongin Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US20090098538A1 (en) 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy
US7914988B1 (en) 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
WO2007140352A2 (en) 2006-05-26 2007-12-06 Invitrogen Corporation Plasma membrane and secreted cancer biomarkers
WO2007149965A2 (en) 2006-06-22 2007-12-27 Wisconsin Alumni Research Foundation Stromal collagen in the diagnosis and characterization of breast cancer
WO2008036717A2 (en) 2006-09-19 2008-03-27 Emory University Use of soluble galectin-3 (gal-3) for cancer treatment
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
WO2008048570A2 (en) 2006-10-16 2008-04-24 The Ohio State University Research Foundation Piwil2-related biomarkers and cell lines useful therewith
WO2008067065A2 (en) * 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
JP2010509598A (ja) 2006-11-13 2010-03-25 ライフ テクノロジーズ コーポレーション 前立腺癌バイオマーカーを検出するための方法およびキット
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20100015620A1 (en) 2006-12-06 2010-01-21 Strovel Jeffrey W Cancer-linked genes as biomarkers to monitor response to impdh inhibitors
AT504702A1 (de) 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
WO2008086342A2 (en) 2007-01-09 2008-07-17 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
US20090047694A1 (en) 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
US20090258795A1 (en) 2007-03-15 2009-10-15 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2008122447A2 (en) 2007-04-10 2008-10-16 Epigenomics Ag Dna methylation assay for the diagnosis or prognosis of medical conditions
AU2008251381B2 (en) 2007-05-11 2014-10-30 The Johns Hopkins University Biomarkers for melanoma
EP2068618A4 (en) 2007-05-21 2011-01-19 Dana Farber Cancer Inst Inc COMPOSITIONS AND METHODS OF DISCOVERING TUMOR GENES
WO2009021338A1 (en) 2007-08-15 2009-02-19 UNIVERSITé DE SHERBROOKE Alternative splicing gene variants in cancer detection
JP2010537658A (ja) 2007-09-07 2010-12-09 ユニヴェルシテ リブル ドゥ ブリュッセル Ｈｅｒ２＋患者におけるガンの予後判定のための方法およびツール
WO2009051734A1 (en) 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
GB0721605D0 (en) 2007-11-02 2007-12-12 Cancer Rec Tech Ltd Prostrate cancer susceptibility screening
US20090123439A1 (en) 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
WO2009070767A2 (en) 2007-11-28 2009-06-04 Whitehead Institute For Biomedical Research Systemic instigation systems to study tumor growth or metastasis
EP2065474A1 (en) 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic response to endocrine treatment
US9932639B2 (en) 2007-11-30 2018-04-03 Ralph Markus Wirtz Method for predicting therapy responsiveness in basal like tumors
WO2009089521A2 (en) 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy
WO2009105154A2 (en) 2008-02-19 2009-08-27 The Jackson Laboratory Diagnostic and prognostic methods for cancer
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
NZ627239A (en) 2008-03-26 2015-12-24 Theranos Inc Methods and systems for assessing clinical outcomes
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
US20110053804A1 (en) 2008-04-03 2011-03-03 Sloan-Kettering Institute For Cancer Research Gene Signatures for the Prognosis of Cancer
CA2719172C (en) 2008-04-10 2020-08-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in erg8 gene expression and detection and treatment methods based on those alterations
CA2722424A1 (en) 2008-04-25 2009-10-29 Integrated Bioscience Solutions, Llc Cytological methods for detecting cancer
US8093000B2 (en) 2008-05-09 2012-01-10 The Regents Of The University Of California Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
JP2011521215A (ja) 2008-05-14 2011-07-21 エーテーハー チューリヒ 前立腺癌の診断及び治療のためのバイオマーカー及び薬剤標的発見法、並びにそれを用いて決定されるバイオマーカーアッセイ
WO2009139915A2 (en) 2008-05-15 2009-11-19 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
WO2009140741A1 (en) 2008-05-23 2009-11-26 The University Of Queensland Agents and methods for diagnosing the presence or risk of prostate cancer
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
GB0809689D0 (en) 2008-05-28 2008-07-02 Cancer Res Inst Royal Markers for prostate cancee
WO2009149166A2 (en) 2008-06-03 2009-12-10 Children's Hospital Medical Center Methods and compositions for the diagnosis and treatment of proliferative disorders
WO2010003773A1 (en) 2008-06-16 2010-01-14 Siemens Medical Solutions Diagnostics Gmbh Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
CA2730277A1 (en) 2008-07-08 2010-01-14 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for predicting the survivability of prostate cancer subjects
JP2011528442A (ja) 2008-07-16 2011-11-17 ディナ ファーバー キャンサー インスティチュート，インコーポレイテッド 前立腺癌に関連した兆候およびｐｃｄｅｔｅｒｍｉｎａｎｔ、ならびにそれらの使用方法
AU2009274563A1 (en) 2008-07-21 2010-01-28 Texas A & M University Methods for diagnosis and prognosis of skin cancer
US9103819B2 (en) 2008-09-10 2015-08-11 Rheinische Friedrich-Wilhelms-Universität Bonn Peripheral zone tumor cells, methods for their preparation and use
EP2350316B1 (en) 2008-10-20 2014-04-16 ValiPharma Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes
KR20110073534A (ko) 2008-10-22 2011-06-29 제넨테크, 인크. 전립선 줄기 세포 및 그의 용도
JP2012507300A (ja) 2008-10-30 2012-03-29 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Ｒｎａパターンを評価する方法
WO2010056351A2 (en) 2008-11-14 2010-05-20 Stc.Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia
GB0821787D0 (en) 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
US20110236903A1 (en) 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
CA2748823A1 (en) 2009-01-06 2010-07-15 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for the identification, monitoring, and treatment of prostate cancer
EP3118328A1 (en) 2009-01-07 2017-01-18 Myriad Genetics, Inc. Cancer biomarkers
JP5907732B2 (ja) 2009-01-14 2016-04-26 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 比に基づく生体マーカーおよびそれを使用する方法
CA2749817A1 (en) 2009-01-15 2010-07-22 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of her-2 expression
EP2233590A1 (en) 2009-01-28 2010-09-29 AIT Austrian Institute of Technology GmbH Methylation assay
WO2010096734A2 (en) 2009-02-20 2010-08-26 John Wayne Cancer Institute B7-h3 antibody coupled bead assay for isolation and detection of circulating tumor cells in body fluids of melanoma and breast cancer patients
WO2010099577A1 (en) 2009-03-04 2010-09-10 The University Of Queensland Cancer biomarkers and uses therefor
US8639733B2 (en) 2009-03-16 2014-01-28 Apple Inc. Automatic identification of compatible applications and accessories
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
EP2241634A1 (en) 2009-04-16 2010-10-20 Université Libre de Bruxelles Diagnostic method and tools to predict the effiacy of targeted agents against IGF-1 pathway activation in cancer
CN105132544A (zh) 2009-04-16 2015-12-09 加拿大国家研究委员会 用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组
WO2010127399A1 (en) 2009-05-06 2010-11-11 Walter And Eliza Hall Institute Of Medical Research Gene expression profiles and uses thereof
WO2010129965A1 (en) 2009-05-08 2010-11-11 The Regents Of The University Of California Cancer specific mitotic network
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
AU2010270227B2 (en) 2009-07-08 2015-01-22 Worldwide Innovative Network Method for predicting efficacy of drugs in a patient
WO2011039734A2 (en) 2009-10-02 2011-04-07 Enzo Medico Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
CA2776751C (en) 2009-11-23 2019-07-02 Genomic Health, Inc. Methods to predict clinical outcome of cancer
EP2524055A4 (en) 2010-01-11 2013-06-05 Genomic Health Inc METHOD FOR THE USE OF GENE EXPRESSION FOR DETERMINING THE PROBABILITY OF CLINICAL EXERCISE OF KIDNEY CANCER
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
WO2014108896A1 (en) 2013-01-08 2014-07-17 Marpe Technologies Ltd. Device and method for body moles mapping and tracking

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005008213A2 (en) * 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20090233279A1 (en) * 2005-03-16 2009-09-17 Sidney Kimmel Cancer Center Methods and Compositions for Predicting Death from Cancer and Prostate Cancer Survival Using Gene Expression Signatures
US20070212702A1 (en) * 2005-09-12 2007-09-13 Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20090298082A1 (en) * 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
WO2010056993A2 (en) * 2008-11-14 2010-05-20 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF PATHOLOGY, 2005, 205, PP359-376, JPN6015033948, ISSN: 0003140453 *
THE PROSTATE, 2003, 54, PP34-43, JPN6015033951, ISSN: 0003140454 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019013255A (ja) * 2012-01-31 2019-01-31 ジェノミック ヘルス， インコーポレイテッド 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
JP2017509351A (ja) * 2013-12-30 2017-04-06 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 前立腺癌遺伝子プロファイル及びその使用方法
JP2018527883A (ja) * 2015-05-29 2018-09-27 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 前立腺がん予後判定の方法
JP2023113680A (ja) * 2019-05-31 2023-08-16 医薬資源研究所株式会社 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体

Also Published As

Publication number Publication date
EP4083233A3 (en) 2023-01-25
IL251403B (en) 2018-04-30
ES2925983T3 (es) 2022-10-20
MX346031B (es) 2017-03-01
EP3147373A1 (en) 2017-03-29
EP3556870B9 (en) 2022-09-28
EP2598659B1 (en) 2015-03-11
CA3081061A1 (en) 2012-02-02
JP6246845B2 (ja) 2017-12-13
AU2011282892A1 (en) 2013-03-07
JP2016178921A (ja) 2016-10-13
US10260104B2 (en) 2019-04-16
US20220396842A1 (en) 2022-12-15
IL243201A (en) 2017-04-30
JP7042784B2 (ja) 2022-03-28
MX2018011725A (es) 2021-11-16
HK1212395A1 (en) 2016-06-10
US20200255911A1 (en) 2020-08-13
CA2804626C (en) 2020-07-28
ES2537403T3 (es) 2015-06-08
IL251403A0 (en) 2017-05-29
JP2018068299A (ja) 2018-05-10
WO2012015765A2 (en) 2012-02-02
IL243205A (en) 2017-04-30
MX2013000996A (es) 2013-12-09
WO2012015765A3 (en) 2012-06-14
MX338883B (es) 2016-05-04
JP2020031642A (ja) 2020-03-05
EP2598659A2 (en) 2013-06-05
SG10201505769PA (en) 2015-09-29
US20120028264A1 (en) 2012-02-02
EP3147373B1 (en) 2019-05-15
US20250129432A1 (en) 2025-04-24
EP4083233A2 (en) 2022-11-02
EP3556870A1 (en) 2019-10-23
HK1185116A1 (en) 2014-02-07
SG10201912361VA (en) 2020-02-27
EP2913405B1 (en) 2016-11-09
EP2913405A1 (en) 2015-09-02
NZ607282A (en) 2014-06-27
ES2741745T3 (es) 2020-02-12
IL243203A (en) 2017-04-30
US20190249260A1 (en) 2019-08-15
JP2022031750A (ja) 2022-02-22
EP3556870B1 (en) 2022-06-22
AU2011282892B2 (en) 2015-07-16
DK2598659T3 (en) 2015-05-26
DK2913405T3 (en) 2017-02-13
IL243206A (en) 2017-04-30
SG186940A1 (en) 2013-02-28
US20160097105A1 (en) 2016-04-07
EP2598659A4 (en) 2014-01-01
ES2611000T3 (es) 2017-05-04
DK3147373T3 (da) 2019-08-12
CA3081061C (en) 2023-01-03
MX359416B (es) 2018-09-27
CA2804626A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
JP7042784B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP7042717B2 (ja) 癌の臨床転帰を予測する方法
JP6351112B2 (ja) 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
US11551782B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
KR102376220B1 (ko) 전립선암에서 후기 임상적 종점을 평가하기 위한 알고리즘 및 방법
AU2017268510A1 (en) Method for using gene expression to determine prognosis of prostate cancer
US20110287958A1 (en) Method for Using Gene Expression to Determine Colorectal Tumor Stage
HK40052881A (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
HK40014990A (en) Methods to predict clinical outcome of cancer
NZ752676B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
HK1223132B (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
NZ711680B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160415